Pipéracilline may be available in the countries listed below.
Pipéracilline (DCF) is known as Piperacillin in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Potassium Aguettant phosphate may be available in the countries listed below.
Potassium Phosphate, Monobasic is reported as an ingredient of Potassium Aguettant phosphate in the following countries:
International Drug Name Search
Multi Clens may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Multi Clens in the following countries:
International Drug Name Search
Méthotrexate may be available in the countries listed below.
Méthotrexate (DCF) is known as Methotrexate in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Nimadorm may be available in the countries listed below.
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Nimadorm in the following countries:
International Drug Name Search
MetoHexal Succ comp may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of MetoHexal Succ comp in the following countries:
Metoprolol succinate (a derivative of Metoprolol) is reported as an ingredient of MetoHexal Succ comp in the following countries:
International Drug Name Search
Dexa-Allvoran may be available in the countries listed below.
Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexa-Allvoran in the following countries:
International Drug Name Search
Caprimec may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Abamectin is reported as an ingredient of Caprimec in the following countries:
International Drug Name Search
Morantel Citrate may be available in the countries listed below.
Morantel Citrate (BANM) is also known as Morantel (Prop.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
Dalparan may be available in the countries listed below.
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Dalparan in the following countries:
International Drug Name Search
Relieving symptoms of runny nose and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Tri-Histine Elixir is an antihistamine combination. It works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Tri-Histine Elixir. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Tri-Histine Elixir. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Tri-Histine Elixir may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Tri-Histine Elixir as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Tri-Histine Elixir.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Tri-Histine side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Tri-Histine Elixir at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tri-Histine Elixir out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Tri-Histine Elixir. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Mekitack may be available in the countries listed below.
Tizanidine hydrochloride (a derivative of Tizanidine) is reported as an ingredient of Mekitack in the following countries:
International Drug Name Search
Tamsunar may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsunar in the following countries:
International Drug Name Search
Xylometazoline HCl A may be available in the countries listed below.
Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Xylometazoline HCl A in the following countries:
International Drug Name Search
Melkaick may be available in the countries listed below.
Bromperidol is reported as an ingredient of Melkaick in the following countries:
International Drug Name Search
Zolpidem Tartrate 10mg Tablets
Each tablet contains 10 mg of Zolpidem tartrate.
For excipients see 6.1.
Film coated tablet.
White, oval, biconvex, film-coated tablets, embossed with “ZIM” on one side and “10” on the other.
Zolpidem Tablets are used as a short-term treatment for patients who are suffering from incapacitating insomnia or where insomnia is causing severe distress.
The dose should be taken at night not less than one hour after food. Zolpidem acts rapidly and therefore should be taken immediately before retiring, or in bed.
Adults:
Daily dose of 10mg
Elderly or debilitated:
Daily dose of 5mg as these patients are likely to be more susceptible to the effects of zolpidem tablets.
Children:
Should not be used in children.
Hepatic impairment:
A dose of 5mg per day should be given as the clearance and metabolism of zolpidem is decreased in those with liver problems. Particular caution should be exercised in elderly patients with hepatic impairment. If an inadequate therapeutic effect has been observed and the drug is well tolerated in adults under the age of 65, the dose may be increased to 10mg.
The total recommended daily doses should not be exceeded.
Long term use is not recommended, as with all hypnotics, and the treatment schedule should therefore not last longer than 4 weeks. Treatment duration can vary from a few days to 2 weeks, with a maximum of 4 weeks to include gradual withdrawal where indicated.
Method of Administration
Oral
Zolpidem tablets are contraindicated in the following circumstances:
- Hypersensitivity to zolpidem or any of the excipients in the tablet
- Obstructive sleep apnoea
- Myasthenia gravis
- Severe hepatic insufficiency
- Acute pulmonary insufficiency
- Respiratory depression
- Use in children
- Use in patients with psychotic illness
Before using a hypnotic such as zolpidem tablets the underlying condition should be assessed, identified and treated where possible. If treatment has failed to alleviate the patient's insomnia after 7 - 14 days this may be a sign that a primary psychiatric or physical disorder is present and the cause should therefore be investigated.
Use in Depression: If patients are showing depressive symptomology, zolpidem should be administered with caution. Due to possible suicidal ideation and the risk of intentional overdose by the patient, the quantity of zolpidem prescribed should be the smallest appropriate amount.
Use in patients with a history of drug or alcohol abuse: If patients have a history of drug, alcohol or substance abuse, great caution should be taken when prescribing zolpidem. Due to the high risk of habituation and psychological dependence, patients should be kept under close observation.
Use in Elderly: Caution is advised when prescribing for the elderly as they have increased sensitivity to zolpidem and are more likely to suffer from side effects.
When prescribing benzodiazepines or other hypnotic medications, the following information should be taken into account:
Tolerance: After continuous use for a few weeks there may be a loss of efficacy in the hypnotic effect of short acting drugs such as Zolpidem Tablets.
Dependence: There is a risk of physical and psychological dependence developing when benzodiazepines or benzodiazepine type drugs are used. The probability of dependence increases with the dose, the length of treatment and if the drug has a short duration of action. The risk is also increased in those people who have a history of substance abuse. If physical dependence has developed, withdrawal symptoms are likely if treatment is suddenly discontinued. These symptoms may include headache, depression, muscle pain, irritability, confusion, great anxiety and tension. Sometimes severe withdrawal effects are seen and these consist of derealisation, depersonalisation, hyperacusis, numbness and tingling of extremities, hypersensitivity to light, noise and physical contact, hallucinations and epileptic seizures.
Rebound Insomnia: On withdrawal of a benzodiazepine or benzodiazepine-like drug, the symptoms that originally prompted treatment may return in a heightened form. This recurrence, although transient, may also include other phenomena such as mood changes, anxiety and restlessness. It is important that the patient is informed about the possibility of this occurrence so their anxiety can be constrained if such symptoms arise. As abrupt cessation of the treatment is associated with withdrawal and rebound symptoms, if possible the dosage should be gradually reduced. It is thought that if a drug has a short duration of action these types of withdrawal symptoms can be seen between doses. This phenomenon is particularly observed in patients on high doses.
Amnesia: Patients should take the tablets at such a time as to ensure that they can sleep uninterrupted for 7-8 hours. This is because there is a risk of anterograde amnesia and this usually begins a few hours after the product has been ingested.
Psychiatric and 'Paradoxical' side-effects: There have been reports of behavioural side-effects that sometimes occur when patients, especially the elderly, take benzodiazepines or benzodiazepine type drugs. These adverse reactions include restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses and inappropriate behaviour. If such side-effects occur, Zolpidem Tablets should be discontinued.
Alcohol should not be taken concurrently as the sedative effect of zolpidem may be increased.
Caution Advised:
Zolpidem should be used with caution when the patient is taking CNS depressants, as the depressant effect of the drugs may be magnified. Caution should therefore be taken when treating with
- Antipsychotics (neuroleptics)
- Hypnotics
- Anxiolytics/sedatives
- Antidepressant agents
- Narcotic analgesics
- Antiepileptics drugs
- Anaesthetics
- Sedative antihistamines
Concomitant use with narcotic analgesics may increase euphoria and therefore may contribute to an increase in psychological dependence.
The action of benzodiazepines and benzodiazepine type agents may be enhanced by drugs which inhibit certain hepatic enzymes, especially the cytochrome P450 enzyme.
Safety in pregnancy has not been established although no teratogenic or embryotoxic effects have been reported in animals. Zolpidem should be avoided in pregnancy, particularly during the first trimester.
Women of child bearing age should be informed that they should contact their doctor if they intend to become or suspect that they are pregnant.
If Zolpidem is used for urgent medical reasons during the late phase of pregnancy or during labour, the neonate may be effected by hypothermia, hypotonia and moderate respiratory depression as a result of the pharmacological action of the drug.
Mothers who take benzodiazepines or benzodiazepine like drugs persistently during pregnancy may give birth to babies that have developed physical dependence and so may develop withdrawal symptoms in the postnatal period.
Use of Zolpidem is not recommended for lactating mothers as Zolpidem appears in small quantities in the breast milk.
Simulated car driving tests have shown that on the day after taking the medicine driving was not affected. However due to the possible risk of drowsiness in the morning after treatment, those who drive vehicles and operate machines should be warned of the possible danger.
As the sedative effect of zolpidem may be increased with the concurrent intake of alcohol, which could then affect the patient's ability to drive or use machinery, those who drive vehicles and operate machines should be warned of the possible danger.
There is evidence of a dose-relationship for adverse effects associated with zolpidem use, particularly for certain CNS and gastrointestinal events. These adverse effects are seen more frequently in elderly patients.
The most frequently documented undesirable effects seen after taking Zolpidem are daytime drowsiness, dizziness, diarrhoea, headache, nausea, vomiting, weakness and vertigo.
More rare reactions that have been identified include memory disturbances (anterograde amnesia), nightmares, nocturnal restlessness, depressive syndrome, episodes of confusion, perceptual disturbances or diplopia, tremor, unsteady gait and falls. The likelihood of amnesia is not related to dose or age.
When zolpidem is the sole drug taken, it has been found that consciousness is impaired and ranges from somnolence to light coma. Patients who have taken up to 40 times the daily dose, 400mg, have fully recovered.
Symptomatic and supportive measures should be taken, and where appropriate gastric lavage should be used and intravenous fluids should be given. If 100mg or more of zolpidem has been ingested, gastric lavage should be performed and the patient observed for at least 12 hours. Activated charcoal should be used to reduce absorption if emptying of the stomach is not appropriate. Sedating drugs should be withheld even if excitation occurs. Use of flumazenil may be considered where serious symptoms are observed.
As with all overdoses consideration needs to be given to the fact more than one drug may have been taken.
Zolpidem is an imidazopyridine, and as such it is a GABA-A receptor agonist that selectively binds the omega-1 receptor subtype (also known as the benzodiazepine-1 subtype or BZ-1) which is the alpha unit of the GABA-A receptor complex. Benzodiazepines bind to all 3 omega receptor subtypes, but zolpidem selectively binds to the omega-1, the BZ1 receptor. It is thought that this selectivity is the reason that zolpidem is potent as a sedative as opposed to a muscle relaxant, anti-convulsant or minor anxiolytic. The sedative effect is gained by the modulation of the chloride anion channel via this receptor.
The effects of zolpidem are reversed by flumazenil, which is a benzodiazepine antagonist.
In animals: The myorelaxant and anticonvulsant properties that are usually seen in benzodiazepines are not present at hypnotic doses of zolpidem. It is believed that this is due to the selectivity for the omega-1 sites in the brain.
In humans: Deep sleep (stage 3 and 4 of slow wave sleep) is unchanged after treatment with Zolpidem. Again it is thought to be as a result of the selectivity to the omega 1 binding site.
Zolpidem has both a rapid absorption and onset of hypnotic action.
Bioavailability is 70% following oral administration and demonstrates linear kinetics in the therapeutic dose range. C max is reached at between 0.5 and 3 hours. A night-time food interaction study showed a 15% reduction in AUC and a 25% reduction in Cmax.
It is widely distributed throughout the body. The volume of distribution in adults is 0.54±0.02 L/kg and decreases to 0.34±0.05 L/kg in the elderly.
Protein binding amounts to 92.5%±0.1%. After repeated doses the drug does not accumulate and protein binding is unchanged.
Zolpidem undergoes first pass metabolism in the liver. The metabolites are not pharmacologically active.
The elimination half-life is short, with a mean of 2.4 hours (0.7-0.3.5) and a duration of action up to 6 hours. Zolpidem is almost entirely eliminated by the liver with 79-96% of the dose appearing as metabolites in the urine (56%) and faeces (37%). Less than 1% is excreted unchanged in the urine.
Zolpidem is not removed by haemodialysis.
In the elderly and patients with hepatic with hepatic impairment, the plasma concentrations are increased, and the clearance and volume of distribution are reduced. In patients with renal problems there may be a moderate reduction in clearance, even after dialysis, although there is no need for dose adjustment. Other pharmacokinetic parameters are unaffected.
Preclinical data revealed no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity, gentotoxicity, carcinogenic potential, toxicity to reproduction.
Tablet core:
Lactose monohydrate
Microcrystalline cellulose
Sodium starch glycollate
Hypromellose
Magnesium stearate
Film coat:
Hypromellose
Titanium dioxide (E171)
Macrogol 400
None Known
36 months
Store in the original package.
PVC/PE/PVDC/Al blister
HDPE containers sealed with an aluminium seal, and closed with a child resistant PP closure.
10, 28, 100
Not Applicable
Lagap Pharmaceuticals Ltd
Woolmer Way
Bordon
Hampshire GU35 9QE
PL 4416/0365
25/03/2009
25/03/2009
Magnesia may be available in the countries listed below.
Magnesium Hydroxide is reported as an ingredient of Magnesia in the following countries:
International Drug Name Search
ten-EK-te-plase
In the U.S.
Available Dosage Forms:
Therapeutic Class: Thrombolytic
Pharmacologic Class: Tissue Plasminogen Activator
Tenecteplase is used to dissolve blood clots that have formed in the blood vessels of the heart and seriously lessen the flow of blood in the heart. tenecteplase is used to improve survival after a heart attack.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For tenecteplase, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to tenecteplase or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Children—Studies on tenecteplase have been done only in adult patients, and there is no specific information comparing use of tenecteplase in children with use in other age groups.
The need for treatment with tenecteplase may be increased in elderly patients with blood clots. However, the chance of bleeding may also be increased. It is especially important that you discuss the use of tenecteplase with your doctor.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving tenecteplase, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using tenecteplase with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using tenecteplase with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of tenecteplase. Make sure you tell your doctor if you have any other medical problems, especially:
Also, tell your doctor if you have recently had any of the following conditions:
If you have recently had a baby, use of tenecteplase may cause serious bleeding.
The dose of tenecteplase will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of tenecteplase. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Tenecteplase can cause bleeding that usually is not serious. However, serious bleeding may occur in some people. To help prevent serious bleeding, carefully follow any instructions given by your health care professional. Also, move around and be handled as little as possible, and do not get out of bed on your own, unless your health care professional tells you it is all right to do so.
Do not take other medicines unless they have been discussed with your doctor. This especially includes nonprescription medicines, such as aspirin.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Generic Name: chloroxylenol, hydrocortisone, and pramoxine (otic) (KLOR oh ZYE nol, HYE droe KOR ti sone, pra MOX een)
Brand Names: Aero Otic HC, Cortamox, Cortane-B, Cortane-B Aqueous, Cortane-B Otic, Cortic-ND, Cyotic, Exotic-HC, Hydro Ear, IvDerm, Otirx, Oto-End, Otomar HC, Tri-Otic, Zolene HC, Zoto-HC Drops
Chloroxylenol is an antibiotic that fights bacteria.
Pramoxine is a topical anesthetic. It works by interfering with pain signals sent from the nerves to the brain.
Hydrocortisone is a steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.
The combination of chloroxylenol, hydrocortisone, and pramoxine otic (for the ear) are used to treat pain, and swelling caused by ear infections.
Chloroxylenol, hydrocortisone, and pramoxine otic may also be used for other purposes not listed in this medication guide.
Before using chloroxylenol, hydrocortisone, and pramoxine, tell your doctor if you are allergic to any drugs, or if you have any type of illness or infection (other than an ear infection).
Less serious side effects are more likely, and you may have none at all.
You should not use this medication if you are allergic to chloroxylenol, hydrocortisone, or pramoxine.
Before using chloroxylenol, hydrocortisone, and pramoxine, tell your doctor if you are allergic to any drugs, or if you have any type of illness or infection (other than an ear infection).
Use this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor.
For best results, remove any ear wax or other debris before using the ear drops. Ask your doctor about safe methods of ear wax removal.
To use the ear drops, first remove the cap from the dropper bottle. Lie down or tilt your head with your ear facing upward. Pull back on your ear gently to open up the ear canal. Hold the dropper upside down over your ear canal and place enough drops of the medicine in your ear to fill the ear canal.
After using the ear drops, keep the ear tilted upward for about 5 minutes. You may also be able to soak a small cotton wick with the medication and leave it in place. Ask your doctor of pharmacist for instructions on using a cotton wick.
Wipe the dropper tip with a clean tissue. Do not wash the tip with water or soap.
Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Talk with your doctor if your symptoms do not improve after using this medication.
Use the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to use the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.
An overdose of chloroxylenol, hydrocortisone, and pramoxine applied into the ear is not likely to cause life-threatening symptoms.
ear drainage or discharge;
severe burning or itching in your ear; or
worsening pain, irritation, or rash.
Less serious side effects are more likely, and you may have none at all.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
It is not likely that other drugs you take orally or inject will have an effect on chloroxylenol, hydrocortisone, and hydrocortisone otic. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Mirtazapina Farmoz may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Mirtazapina Farmoz in the following countries:
International Drug Name Search
Mitapillarin may be available in the countries listed below.
Polystyrene Sulfonic Acid calcium salt (a derivative of Polystyrene Sulfonic Acid) is reported as an ingredient of Mitapillarin in the following countries:
International Drug Name Search
Meperidina Chobet may be available in the countries listed below.
Pethidine hydrochloride (a derivative of Pethidine) is reported as an ingredient of Meperidina Chobet in the following countries:
International Drug Name Search
Enocef may be available in the countries listed below.
Ceftriaxone is reported as an ingredient of Enocef in the following countries:
International Drug Name Search
Generic Name: romiplostim (ROM i PLOS tim)
Brand Names: Nplate
Romiplostim is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body.
Romiplostim is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura (ITP), a bleeding condition caused by a lack of platelets in the blood.
Romiplostim is usually given after other medications have been tried without successful treatment of symptoms.
Romiplostim may also be used for other purposes not listed in this medication guide.
Romiplostim is available only under a special program called Nplate NEXUS. You must be enrolled in this program and sign all required agreements in order to receive the medication. Read all program brochures and agreements carefully.
Before you use romiplostim, tell your doctor if you have kidney or liver disease.
It may take up to 4 weeks of using this medicine before it is completely effective in preventing bleeding episodes. Talk with your doctor if you have any bruising or bleeding episodes after 4 weeks of treatment.
If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you use romiplostim, tell your doctor if you have kidney or liver disease.
Your name may need to be listed on a pregnancy registry if you become pregnant while receiving romiplostim. The purpose of this registry is to track the outcome of the pregnancy and delivery to evaluate whether romiplostim had any effect on the baby
Using romiplostim may increase your risk of developing blood cancers, especially if you have myelodysplastic syndrome (also called "preleukemia"). Talk with your doctor if you have concerns about this risk.
Romiplostim is available only under a special program called Nplate NEXUS. You must be enrolled in this program and sign all required agreements in order to receive the medication. Read all program brochures and agreements carefully.
Romiplostim is given as an injection under the skin, usually once per week. Your doctor, nurse, or other healthcare provider will give you this injection.
It may take up to 4 weeks of using this medicine before it is completely effective in preventing bleeding episodes. For best results, keep receiving the medication as directed. Talk with your doctor if you have any bruising or bleeding episodes after 4 weeks of treatment.
Call your doctor for instructions if you miss an appointment for your romiplostim injection.
Overdose can cause signs of a blood clot, including sudden numbness or weakness, sudden headache or confusion, problems with vision or speech, loss of balance, chest pain, sudden cough, wheezing, rapid breathing, fast heart rate, and pain or swelling in one or both legs.
Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using romiplostim.
Less serious side effects may include:
headache;
dizziness;
joint or muscle pain;
pain in your arms, legs, or shoulder;
numbness or tingly feeling;
sleep problems (insomnia); or
stomach pain or upset.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura:
Initial dose: 1 mcg/kg subcutaneous injection based on actual body weight.
Use the lowest dose of romiplostim to achieve and maintain a platelet count greater than or equal to 50 x 10^9/L as necessary to reduce the risk for bleeding. Administer romiplostim as a weekly subcutaneous injection with dose adjustments based upon the platelet count response. Romiplostim should not be used in an attempt to normalize platelet counts.
There may be other drugs that can interact with romiplostim. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: romiplostim side effects (in more detail)
Allergocrom may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Allergocrom in the following countries:
International Drug Name Search
Maxicardil may be available in the countries listed below.
Dipyridamole is reported as an ingredient of Maxicardil in the following countries:
International Drug Name Search
MPA-beta may be available in the countries listed below.
Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of MPA-beta in the following countries:
International Drug Name Search
Mequitolide may be available in the countries listed below.
Mexiletine hydrochloride (a derivative of Mexiletine) is reported as an ingredient of Mequitolide in the following countries:
International Drug Name Search
Sicovit B2 may be available in the countries listed below.
Riboflavin is reported as an ingredient of Sicovit B2 in the following countries:
International Drug Name Search
Venetlin may be available in the countries listed below.
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Venetlin in the following countries:
International Drug Name Search
Amoxicilina Perugen may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Amoxicilina Perugen in the following countries:
International Drug Name Search
Mitaprogen may be available in the countries listed below.
Flopropione is reported as an ingredient of Mitaprogen in the following countries:
International Drug Name Search
Biocid may be available in the countries listed below.
Omeprazole is reported as an ingredient of Biocid in the following countries:
International Drug Name Search
Norditropine Simplexx may be available in the countries listed below.
Somatropine is reported as an ingredient of Norditropine Simplexx in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Bacitracin methylene disalicylate (a derivative of Bacitracin) is reported as an ingredient of Micro CTC in the following countries:
Chlortetracycline is reported as an ingredient of Micro CTC in the following countries:
Chlortetracycline hydrochloride (a derivative of Chlortetracycline) is reported as an ingredient of Micro CTC in the following countries:
International Drug Name Search
Moronal may be available in the countries listed below.
Nystatin is reported as an ingredient of Moronal in the following countries:
International Drug Name Search
Pelias may be available in the countries listed below.
Allylestrenol is reported as an ingredient of Pelias in the following countries:
International Drug Name Search
Meiceral may be available in the countries listed below.
Omeprazole is reported as an ingredient of Meiceral in the following countries:
International Drug Name Search
Panagesic Infantil may be available in the countries listed below.
Paracetamol is reported as an ingredient of Panagesic Infantil in the following countries:
International Drug Name Search
In the US, Mesalamine (mesalamine systemic) is a member of the drug class 5-aminosalicylates and is used to treat Crohn's Disease - Maintenance, Lymphocytic Colitis, Ulcerative Colitis - Active and Ulcerative Colitis - Maintenance.
US matches:
Mesalamine (USAN) is also known as Mesalazine (Rec.INN)
International Drug Name Search
Glossary
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Mycoban may be available in the countries listed below.
Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Mycoban in the following countries:
International Drug Name Search
Treating anxiety, for sedation before and after general anesthesia, and to treat itching due to certain allergic conditions, including hives and contact dermatitis (eg, poison ivy). It also may be used for other conditions as determined by your doctor.
Atarax is an antihistamine. It works by affecting the brain to reduce anxiety. It also has other activities, including opening breathing tubes, relieving pain or allergy symptoms, and preventing or treating nausea and vomiting caused by motion sickness.
Contact your doctor or health care provider right away if any of these apply to you.
Treatments for depression are getting better everyday and there are things you can start doing right away.
Some medical conditions may interact with Atarax. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Atarax. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Atarax may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Atarax as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Atarax.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Drowsiness; dry mouth.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); involuntary movements.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Atarax side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include unusual drowsiness and dizziness.
Store Atarax at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Do not freeze. Store away from heat, moisture, and light in a tightly closed container. Do not store in the bathroom. Keep Atarax out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Atarax. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Menaxol may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Menaxol in the following countries:
International Drug Name Search
Rec.INN
N05AD04
0001050-79-9
C22-H26-F-N-O2
355
Neuroleptic
1-Butanone, 1-(4-fluorophenyl)-4-[4-hydroxy-4-(4-methylphenyl)-1-piperidinyl]-
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Zinolium Aciclovir may be available in the countries listed below.
Aciclovir is reported as an ingredient of Zinolium Aciclovir in the following countries:
International Drug Name Search
| Amount Per Serving | % Daily Value | |
| Vitamin A (as beta carotene) | 2600 IU | 52% |
| Vitamin C (as ascorbic acid) | 120 mg | 200% |
| Vitamin D3 (cholecalciferol) | 420 IU | 105% |
| Vitamin E (as d-alpha tocopheryl succinate) | 20 IU | 67% |
| Vitamin B1 (as thiamine HCl) | 3 mg | 200% |
| Vitamin B2 (as riboflavin) | 3.5 mg | 205% |
| Vitamin B3 (as niacinamide) | 20 mg | 100% |
| Vitamin B6 (as pyridoxine HCl) | 30 mg | 1500% |
| Folic Acid | 1 mg | 250% |
| Vitamin B12 (as cyanocobalamin) | 12 mcg | 200% |
| Biotin | 30 mcg | 10% |
| Pantothenic Acid (as calcium pantothenate) | 8 mg | 80% |
| Calcium (as calcium carbonate and tricalcium phosphate) | 100 mg | 10% |
| Iron (as ferrous bisglycinate) | 26 mg | 144% |
| Magnesium (as magnesium oxide) | 50 mg | 12% |
| Zinc (as zinc oxide) | 15 mg | 100% |
| Selenium (as sodium selenate) | 50 mcg | 71% |
| Copper (as cupric oxide) | 2 mg | 100% |
| Choline (as choline bitartrate) | 60 mg | * |
| *Daily Value not established. |
| Amount Per Serving | % Daily Value | |
| Docosahexaenoic Acid (DHA) | 200 mg | * |
| *Daily Value not established. |
VitaPhil + DHA and VitaPhil + DHA 90 are indicated to provide vitamin/mineral and omega-3 fatty acid supplementation to women throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers and throughout the child bearing years. VitaPhil + DHA and VitaPhil + DHA 90 are also useful in improving the nutritional status prior to conception.
Before, during and after pregnancy, one caplet and one softgel capsule taken by mouth daily, or as prescribed by a physician. The caplet and softgel capsule may be taken together or at different times of the day. Caution should be exercised to ensure that the prescribed dose of DHA does not exceed 1 gram (1,000 mg) per day.
VitaPhil + DHA and VitaPhil + DHA 90 are contraindicated in patients with a known hypersensitivity to any of the ingredients, including fish oil and soy. Iron is contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. These products are contraindicated for persons with pernicious anemia, as folic acid may obscure its signs and symptoms.
Folic acid alone is improper therapy in the treatment of pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive.
Ingestion of omega-3 fatty acids (including alpha-linolenic acid [ALA], eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] from fish oils) of more than 3 grams per day may present antithrombotic effects, including increased bleeding time. Omega-3 fatty acids including DHA and EPA should be avoided in patients with inherited or acquired bleeding diatheses. Patients taking anticoagulant drug products should consult with their physician prior to ingesting omega-3 fatty acids.
Folic acid in dosages above 400 mcg daily may obscure megaloblastic (pernicious) anemia in that hematological remission can occur while neurological manifestations (Addisonian anemia) remain progressive.
Iron: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) can occur but are usually mild and can subside with continuation of therapy. Although the absorption of iron is best when taken between meals, VitaPhil + DHA and VitaPhil + DHA 90 when taken after meals, may control occasional G.I. disturbances. VitaPhil + DHA and VitaPhil + DHA 90 are best absorbed when taken at bedtime.
Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.
Call your doctor for medical advice about side effects. You may report suspected side effects to the FDA at 1-800-FDA-1088.
VitaPhil + DHA and VitaPhil + DHA 90 are not advocated for pediatric or geriatric use.
Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting. In severe cases, iron overdose can cause cardiovascular collapse and death. Other symptoms include pallor and cyanosis, melena, shock, drowsiness and coma. The estimated overdose of orally ingested iron is 300mg/kg body weight. When overdoses are ingested by children, severe reactions, including fatalities have resulted. VitaPhil + DHA and VitaPhil + DHA 90 should be stored beyond the reach of children to prevent against accidental iron poisoning. Keep this and all other drugs out of reach of children. Treatment: For specific therapy, exchange transfusion and chelating agents should be used. For general management, perform gastric lavage with sodium bicarbonate solution or milk. Administer intravenous fluids and electrolytes and use oxygen.
VitaPhil + DHA (NDC 68032-341-60): A 30-day regimen supplied as one bottle containing 30 green VitaPhil + DHA Prenatal capsule-shaped caplets NDC: 68032-496-30 imprinted “RE 341” and one bottle containing 30 pale yellow DHA softgel capsules NDC: 68032-497-30. Dispense in tight, light-resistant containers as defined in the USP/NF with child resistant closures.
VitaPhil + DHA 90 (NDC 68032-342-18): A 90-day regimen supplied as one bottle containing 90 green VitaPhil + DHA 90 Prenatal capsule-shaped caplets NDC: 68032-498-90 imprinted “RE 341” and one bottle containing 90 pale yellow DHA softgel capsules NDC: 68032-499-90. Dispense in tight, light-resistant containers as defined in the USP/NF with child resistant closures.
Store at controlled room temperature 15°-30°C (59°-86°F). Keep in a cool, dry place.
CAUTION: Rx Only
Manufactured for:
River’s Edge Pharmaceuticals, LLC
Suwanee, GA 30024
Iss. 03/10 341/342-11
| VITAPHIL 90 DHA beta carotene, ascorbic acid, cholecalciferol, alpha-tocopherol, thiamine hydrochloride, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, biotin, calcium pantothenate, calcium carbonate, iron, magnesium oxide, zinc oxide, selenium, cupric oxide, choline bitartrate, doconexent kit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 11/14/2008 | 10/30/2010 | |
| Labeler - River's Edge Pharmaceuticals, LLC (133879135) |
